TransCode Therapeutics, Inc.
RNAZ
$6.73
-$0.27-3.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -176.83% | -13.55% | 64.61% | -104.28% | -154.85% |
| Total Depreciation and Amortization | 833.33% | -64.18% | -73.83% | -58.34% | -3.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,088.80% | 41.03% | -96.88% | 451.09% | 733.45% |
| Change in Net Operating Assets | -3.95% | 257.95% | 50.67% | -148.30% | 149.00% |
| Cash from Operations | -99.40% | 2.65% | -35.44% | 1.58% | 19.59% |
| Capital Expenditure | -- | -- | -- | -- | 96.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 96.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | 25.03% | 189.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | -- |
| Cash from Financing | 5,174.41% | -- | -100.00% | 25.03% | 189.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 429.98% | -8.22% | -172.84% | 46.32% | 366.13% |